Literature DB >> 20140624

Effect of type 1 insulin-like growth factor receptor targeted therapy on chemotherapy in human cancer and the mechanisms involved.

Alyse Hopkins1, Philip J Crowe, Jia-Lin Yang.   

Abstract

INTRODUCTION: Chemotherapy is administered only to patients with advanced cancers, typically to modest avail. Hence, the search for innovative approaches to treat cancer is growing rapidly. One such approach involves targeting molecular pathways identified as encouraging tumor growth and maintenance, particularly the type 1 insulin-like growth factor (IGF-1) and its receptor (IGF-1R) pathway that is important in conferring chemoresistance.
MATERIALS AND METHODS: This study focuses on IGF-1R targeted therapy, which will enhance chemotherapy efficacy, through reviewing recent literature from PubMed and Medline databases.
CONCLUSION: This review examines data and strategies addressing an approach conquering chemoresistance through the combination of IGF-1R targeted therapy and chemotherapy in cancer patients, as well as the mechanisms by which IGF-1R acts as a target. This will impact on future research on treatment selection, thereby improving patient prognosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20140624     DOI: 10.1007/s00432-010-0792-0

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  71 in total

Review 1.  The IGF system and breast cancer.

Authors:  D Sachdev; D Yee
Journal:  Endocr Relat Cancer       Date:  2001-09       Impact factor: 5.678

Review 2.  The IGF axis and hepatocarcinogenesis.

Authors:  J G Scharf; F Dombrowski; G Ramadori
Journal:  Mol Pathol       Date:  2001-06

3.  Expression of insulin-like growth factor-1 receptor in synovial sarcoma: association with an aggressive phenotype.

Authors:  Y Xie; B Skytting; G Nilsson; B Brodin; O Larsson
Journal:  Cancer Res       Date:  1999-08-01       Impact factor: 12.701

4.  A new progeroid syndrome reveals that genotoxic stress suppresses the somatotroph axis.

Authors:  Laura J Niedernhofer; George A Garinis; Anja Raams; Astrid S Lalai; Andria Rasile Robinson; Esther Appeldoorn; Hanny Odijk; Roos Oostendorp; Anwaar Ahmad; Wibeke van Leeuwen; Arjan F Theil; Wim Vermeulen; Gijsbertus T J van der Horst; Peter Meinecke; Wim J Kleijer; Jan Vijg; Nicolaas G J Jaspers; Jan H J Hoeijmakers
Journal:  Nature       Date:  2006-12-21       Impact factor: 49.962

5.  Induction of tumor suppression and glandular differentiation of A549 lung carcinoma cells by dominant-negative IGF-I receptor.

Authors:  Y Jiang; W N Rom; T A Yie; C X Chi; K M Tchou-Wong
Journal:  Oncogene       Date:  1999-10-28       Impact factor: 9.867

Review 6.  Tyrosine kinases as targets in cancer therapy - successes and failures.

Authors:  Peter Traxler
Journal:  Expert Opin Ther Targets       Date:  2003-04       Impact factor: 6.902

7.  Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer.

Authors:  Daniel D Karp; Luis G Paz-Ares; Silvia Novello; Paul Haluska; Linda Garland; Felipe Cardenal; L Johnetta Blakely; Peter D Eisenberg; Corey J Langer; George Blumenschein; Faye M Johnson; Stephanie Green; Antonio Gualberto
Journal:  J Clin Oncol       Date:  2009-04-20       Impact factor: 44.544

8.  Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth.

Authors:  Ada Girnita; Leonard Girnita; Fabrizio del Prete; Armando Bartolazzi; Olle Larsson; Magnus Axelson
Journal:  Cancer Res       Date:  2004-01-01       Impact factor: 12.701

9.  Inhibition of insulin-like growth factor I receptor expression in neuroblastoma cells induces the regression of established tumors in mice.

Authors:  X Liu; T Turbyville; A Fritz; L Whitesell
Journal:  Cancer Res       Date:  1998-12-01       Impact factor: 12.701

Review 10.  Opportunities for improving the therapeutic ratio for patients with sarcoma.

Authors:  Jay S Wunder; Torsten O Nielsen; Robert G Maki; Brian O'Sullivan; Benjamin A Alman
Journal:  Lancet Oncol       Date:  2007-06       Impact factor: 41.316

View more
  9 in total

Review 1.  Can we unlock the potential of IGF-1R inhibition in cancer therapy?

Authors:  Helen King; Tamara Aleksic; Paul Haluska; Valentine M Macaulay
Journal:  Cancer Treat Rev       Date:  2014-08-04       Impact factor: 12.111

2.  Insulin-like growth factor 1 regulates growth of endometrial carcinoma through PI3k signaling pathway in insulin-resistant type 2 diabetes.

Authors:  Congwei Dai; Na Li; Guangyao Song; Yanyan Yang; Xiaoran Ning
Journal:  Am J Transl Res       Date:  2016-08-15       Impact factor: 4.060

3.  Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptor.

Authors:  Xianke Zeng; Hua Zhang; Annabell Oh; Yan Zhang; Douglas Yee
Journal:  Breast Cancer Res Treat       Date:  2011-08-18       Impact factor: 4.872

4.  Involvement of miR-143 in cisplatin resistance of gastric cancer cells via targeting IGF1R and BCL2.

Authors:  Ming Zhuang; Qin Shi; Xiuwei Zhang; Yongbin Ding; Liuqun Shan; Xia Shan; Jiaqi Qian; Xin Zhou; Zebo Huang; Wei Zhu; Yin Ding; Wenfang Cheng; Ping Liu; Yongqian Shu
Journal:  Tumour Biol       Date:  2014-12-10

5.  Clinical significance of IGF1R gene expression in patients with Stage II/III gastric cancer who receive curative surgery and adjuvant chemotherapy with S-1.

Authors:  Koji Numata; Takashi Oshima; Kentaro Sakamaki; Kazue Yoshihara; Toru Aoyama; Tsutomu Hayashi; Takanobu Yamada; Tsutomu Sato; Haruhiko Cho; Manabu Shiozawa; Takaki Yoshikawa; Yasushi Rino; Chikara Kunisaki; Makoto Akaike; Toshio Imada; Munetaka Masuda
Journal:  J Cancer Res Clin Oncol       Date:  2015-09-03       Impact factor: 4.553

6.  Identification of common and distinctive mechanisms of resistance to different anti-IGF-IR agents in Ewing's sarcoma.

Authors:  Cecilia Garofalo; Caterina Mancarella; Andrea Grilli; Maria Cristina Manara; Annalisa Astolfi; Maria Teresa Marino; Alexia Conte; Sara Sigismund; Alessandra Carè; Antonino Belfiore; Piero Picci; Katia Scotlandi
Journal:  Mol Endocrinol       Date:  2012-07-13

7.  IGF-1 increases invasive potential of MCF 7 breast cancer cells and induces activation of latent TGF-β1 resulting in epithelial to mesenchymal transition.

Authors:  Logan A Walsh; Sashko Damjanovski
Journal:  Cell Commun Signal       Date:  2011-05-02       Impact factor: 5.712

8.  Marginal effects of glucose, insulin and insulin-like growth factor on chemotherapy response in endothelial and colorectal cancer cells.

Authors:  Ekaterina Volkova; Bridget A Robinson; Jinny Willis; Margaret J Currie; Gabi U Dachs
Journal:  Oncol Lett       Date:  2013-11-27       Impact factor: 2.967

9.  A subset of bone marrow stromal cells regulate ATP-binding cassette gene expression via insulin-like growth factor-I in a leukemia cell line.

Authors:  Nadia Benabbou; Pezhman Mirshahi; Camille Bordu; Anne-Marie Faussat; Ruoping Tang; Amu Therwath; Jeannette Soria; Jean-Pierre Marie; Massoud Mirshahi
Journal:  Int J Oncol       Date:  2014-07-29       Impact factor: 5.650

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.